Gresser I, Maury C, Tovey M
Int J Cancer. 1976 May 15;17(5):647-51. doi: 10.1002/ijc.2910170514.
Daily administration of potent mouse interferon preparations, begun after clinical diagnosis of lymphoma in AKR mice, increased average survival by approximately 100%. Interferon treatment delayed the evolution of the lymphoma but regression of tumour was not observed. The therapeutic effects observed with interferon in AKR mice compare favorably with reported results obtained using standard anti-cancer drugs.
在AKR小鼠淋巴瘤临床诊断后开始每日给予强效小鼠干扰素制剂,平均生存期延长了约100%。干扰素治疗延缓了淋巴瘤的进展,但未观察到肿瘤消退。在AKR小鼠中观察到的干扰素治疗效果与使用标准抗癌药物所报告的结果相比更具优势。